1 min read|50 words
The WHO has prequalified a new artemether–lumefantrine formulation designed specifically for infants, plus 3 rapid diagnostic tests—a major step forward for malaria treatment in sub-Saharan Africa. This regulatory approval enables procurement by UN agencies and addresses a critical gap in paediatric dosing.
Read the full article on GMJ Newsroom →
Was this article helpful?
